TD Cowen analyst Josh Jennings maintained a Buy rating on Anteris Technologies Global Corp. today and set a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight the promising potential of Anteris Technologies Global Corp.’s DurAVR platform. The recent data presented at TCT 2025 from the DurAVR Small Aortic Annuli Pooled Cohort, which includes first-in-human and early feasibility studies, demonstrated outstanding one-year hemodynamic outcomes. These results showcased low gradients, absence of paravalvular leaks, and no prosthesis–patient mismatch, underscoring the effectiveness of the platform’s biomimetic design.
The small annulus cohort data, which included 37 patients with a one-year follow-up, revealed a mean gradient of 8.6mmHg and an effective orifice area of approximately 2.1 cm². This performance is particularly impressive for a small annulus study group, offering a significant advantage over comparable outcomes from the Sapien arm of the SMART trial. Furthermore, the low all-cause mortality rate and absence of valve-related deaths, along with minimal incidence of disabling strokes, reinforce the safety profile of the DurAVR platform. These promising results suggest that DurAVR combines the benefits of low gradients typical of supra-annular self-expanding valves with the procedural control of balloon-expandable systems, making it a compelling investment opportunity.